Clinical outcomes of cetuximab-based treatment for distant metastatic head and neck squamous cell carcinoma: A real-world study using Taiwan Head Neck Society registry database.
Head Neck
; 46(5): 1063-1073, 2024 May.
Article
in En
| MEDLINE
| ID: mdl-38385970
ABSTRACT
BACKGROUND:
For R/M HNSCC, the differences in prognosis and treatment options between distant metastasis (DM) and locoregional recurrence, especially in the DM group, remain unclear.METHODS:
From the Taiwan Head Neck Society registry database, patients who were diagnosed with R/M HNSCC and received cetuximab-based frontline therapy were collected for analysis.RESULTS:
Among the enrolled patients, 59.3% (491/827) belonged to the DM group. The DM group had less primary site of oral cavity, less betel nut chewing, higher lactate dehydrogenase (LDH) levels, and higher LDH/albumin ratio compared with the non-DM group. For the patients with primary site of oral cavity and current smokers, DM coexisted with poorer outcomes. In the DM group, EXTREME-like regimen was more suitable for older patients, those with elevated LDH, and those with higher LDH/albumin ratio than TPExtreme-like regimen.CONCLUSION:
DM coexisted with poorer prognosis in certain groups. LDH-associated biomarkers may aid treatment options for DM patients.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Head and Neck Neoplasms
Limits:
Humans
Country/Region as subject:
Asia
Language:
En
Journal:
Head Neck
Year:
2024
Document type:
Article